MTOR and triple-negative breast carcinoma: Distinctly, under conditions of metabolic and oxidative stress in triple negative breast cancers, we found that mTORC2 activation leads to elevated ATF4 expression, overall suggesting that ATF4 could serve as a biomarker for treatment with mTOR inhibitors in some cancers.